

enteric pathogen containing the NEPA by vaccination by injection followed by oral
administration by feeding the immunoreceptive mammal with [a substance comprising a]
transgenic potato [physiologically acceptable plant material] containing the NEPA expressed in
the [from a transgenic] potato [plant expressing the NEPA] to cause a secondary immune
response to the oral administration specific to the NEPA stronger than a response specific to
NEPA caused by the NEPA in the absence of [prior immunizing] the prior immunization by
injection.

In Claim 3 line 3, please delete "staphylococcus aureous".

Please cancel claims 4-6, 8, 11, and 14-19.

Please change the dependency of Claim 7 from "5" to --2--.

Please change the dependency of Claim 9 from "8" to --7--.

Please change the dependency of Claim 10 from "6" to --9--.

Remarks

This is in response to the official action of October 3, 2000.

The withdrawal of the rejection of claims under 35 U.S.C. 112, of the rejection of Claims 1 under 35 U.S.C. 103 over Koprowski et al. in view of Stites et al., and of Claims 1-2 over Arntzen et al in view of Stites et al. is noted with appreciation.

Claims 1-19 have been rejected under 35 U.S.C. 112 first paragraph for lack of enablement. **This is a new ground of rejection not made necessary by any amendment of the Applicants and has therefore improperly been made final.** The rejection is based upon the allegation that enablement is not provided for providing an immune response to non-enteric